CEL-SCI (CVM) Reports Continued Increase In Sequential Quarterly Patient Enrollment In Its Phase 3 Head And Neck Cancer Trial
6/3/2014 9:51:14 AM
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of May the Company enrolled 14 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). A total of 49 patients were enrolled over the past three months, with 14 patients enrolled in March, 21 in April, and 14 in May of 2014. This marks a continued increase over the prior three month period when a total of 18 patients had been enrolled, with 4 enrolled in December 2013, 8 in January, and 6 in February 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by